PYC Therapeutics Limited
PYC Therapeutics Limited
Your view on PYC.AX
Overview
What the company does, where it operates, and who runs it.
About PYC Therapeutics Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Rohan Hockings
- Headquarters
- Harry Perkins Institute of Medical Research, Nedlands, WA, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Rohan Hockings
- Headquarters
- Harry Perkins Institute of Medical Research, Nedlands, WA, AU
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.
The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which is in pre-clinical studies; and PYC-003 to treat autosomal dominant polycystic kidney disease, which is in early-stage clinical trials.
PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019.
PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for PYC Therapeutics Limited. Starting points for PYC Therapeutics Limited: EPS -AUD 0.04, beta 1.04 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for PYC Therapeutics Limited. PYC Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for PYC Therapeutics Limited. Trailing twelve-month EPS for PYC Therapeutics Limited stands at -AUD 0.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for PYC Therapeutics Limited. PYC Therapeutics Limited has reported as a listed company since 2024. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PALIPalisade Bio, Inc. | Healthcare | NASDAQ | $150.6M | ||
| PANCPanacos Pharmaceuticals, Inc. | Healthcare | OTC | $5,367 | ||
| PAR.AXParadigm Biopharmaceuticals Limited | Healthcare | ASX | — | ||
| PARDPoniard Pharmaceuticals, Inc. | Healthcare | OTC | $150 | ||
| PASGPassage Bio, Inc. | Healthcare | NASDAQ | $12.6M | ||
| PBIGFParadigm Biopharmaceuticals Limited | Healthcare | OTC | $87.9M | ||
| PBLAPanbela Therapeutics, Inc. | Healthcare | OTC | $53,889 | ||
| PBLSParabilis Medicines, Inc. | Healthcare | NASDAQ | $3.3B | ||
| PBMPsyence Biomedical Ltd. | Healthcare | NASDAQ | $56,486 | ||
| PBMWWPsyence Biomedical Ltd. Warrant | Healthcare | NASDAQ | $973 | ||
| PBYIPuma Biotechnology, Inc. | Healthcare | NASDAQ | $364.5M | ||
| PCSAProcessa Pharmaceuticals, Inc. | Healthcare | NASDAQ | $4.4M | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for PYC Therapeutics Limited. Coverage tracks PYC Therapeutics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of PYC Therapeutics Limited.